[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Pages 6879-6880]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02466]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240-669-5299; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement may be required to receive any 
unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows:

Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection

Description of Technology

    The ongoing COVID-19 pandemic, caused by severe respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has

[[Page 6880]]

created an immense public health, social, and economic burden. Variants 
of concern continue to emerge that have increased transmissibility, 
pathogenicity, or both and that reduce the effectiveness of current 
therapeutics and vaccines. Thus, there is a great need for broadly 
protective therapeutics.
    This technology relates to two monoclonal antibodies targeting the 
spike protein of SARS-CoV-2 that between the two have picomolar 
activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, and 
Omicron variants of concern. Additionally, one of the antibodies 
recognizes a highly-conserved epitope of the spike protein. Treatment 
with either monoclonal antibody before or after challenge with SARS-
CoV-2 reduced symptoms and viral load in nasal turbinate and lung 
tissue in the golden Syrian hamster model. This monoclonal antibody 
technology has great potential to treat SARS-CoV-2 infections and may 
provide protection against future variants of concern.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

 Treatment for SARS-CoV-2 infection
 Prophylaxis treatment to prevent or reduce SARS-CoV-2 
infection
 Diagnostic for SARS-CoV-2 infection

Competitive Advantages

 Broad and potent neutralization of several variants of 
concern, including Omicron

Development Stage

     In vivo data assessment (animal)
    Inventors: Zhaochun Chen (NIAID); Patrizia Farci (NIAID); Kamille 
West (CC); Peng Zhang (NIAID); Paolo Lusso (NIAID); Ulla Buchholz 
(NIAID); Yumiko Matsuoka (NIAID).
    Intellectual Property: HHS Reference No. E-132-2021- U.S. 
Provisional Application No. 63/296,380, filed January 4, 2022.
    Licensing Contact: To license this technology, please contact 
Elizabeth Pitts, Ph.D., 240-669-5299; [email protected], and 
reference E-132-2021.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Elizabeth Pitts, Ph.D., 240-669-5299; 
[email protected].

    Dated: February 1, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-02466 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P